(MENAFN - Comserve) Shibuya-ku, Tokyo, Japan, Japan, May 05, 2021, 04:41 /Comserve / -- The report analyze market size, share, growth, trends, segmentation, top key players, strategies, demand, statistics, competitive landscape and forecast.
Hemophilia market is expected to witness a CAGR of 5.9% during the forecast period. Certain factors that are driving the market growth include growing prevalence of hemophilia, favorable government initiatives, and rising R & D and new product development.
Hemophilia, a genetic bleeding disorder that prevents the blood from clotting normally affects 1 in 5,000 male births. About 400 babies are born with hemophilia each year in the United States. According to the World Health Organization (WHO), owing to the sex-linkage of the disorder, there is a bigger prominence in males than in females. About 1/3rd of new diagnoses are where there is no earlier family history. It appears worldwide and is observed across all racial groups. About 6,000 people are suffering from haemophilia in the United Kingdom (as in 2018). There are approximately 5400 people in the UK with haemophilia A and about 1100 with haemophilia B. Hence the high prevalence of the disease is acting as one of the factors fueling the market growth all across the globe.
Key Market Trends
Click Here to Download Sample Report >>
Hemophilia A is Expected to Hold Significant Market Share in the Disease Type Segment
According to the National Hemophilia Foundation (NHF), the United States, the two major forms of hemophilia occur much more frequently in males than in females. Hemophilia A is the most prevalent type of condition with the incidence rate of 1 in 4,000 to 1 in 5,000 males worldwide who are born with this disorder. Whereas Hemophilia B occurs in approximately 1 in 20,000 newborn males all across the globe. The key medication to treat hemophilia A has concentrated FVIII product, also called clotting factor or simply factor. Recombinant factor products, that are developed in a laboratory through the use of DNA technology, impede the use of human-derived pools of donor-sourced plasma. And while plasma-derived FVIII products are still available, approximately 75% of the hemophilia-affected community takes a recombinant FVIII product (as per the NHF).
North America Dominates the Market and Expected to do Same in the Forecast Period
NHF (National Health Federation) is an organization that has been awarding grants and fellowships in order to support innovative research intended for finding better treatments and cures for several bleeding disorders. Such researches have led to vital insights into improved factor replacement therapies, along with more accurate hemophilia diagnostic methods and therefore definitely a greater understanding of the genetic basis of the disease. Through the efforts and guidance of NHF's Medical and Scientific Advisory Council (MASAC), an internationally distinguished group of expert scientists, physicians as well as other treatment specialists, NHF has been engaged since long in advancing the standard of clinical care and issuing treatment recommendations for hemophilia. Moreover, NHF states that the number of people with hemophilia in the United States is estimated to be about 20,000 individuals in 2019. Hence, owing to the rising prevalence of the disease along with the growing initiatives by several organizations is driving the market growth in the region.
The Hemophilia market is highly competitive and consists of a few major players. Companies like Bayer AG, BioMarin Pharmaceutical, Inc., CSL Behring, Kedrion, Novo Nordisk, Pfizer, Inc., Roche (Chugai Pharmaceutical Co.), Sanofi (Genzyme Corporation), Takeda Pharmaceutical (Shire Plc.)., among others, hold the substantial market share in the Hemophilia market.
Reasons to Purchase this report:
- The market estimate (ME) sheet in Excel format
- 3 months of analyst support
Request For Full Report >>
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study
2 RESEARCH METHODOLOGY
3 EXECUTIVE SUMMARY
4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Growing Prevalence of Hemophilia
4.2.2 Favorable Government Initiatives
4.2.3 Rising R & D and New Product Development
4.3 Market Restraints
4.3.1 High Cost of Treatment
4.3.2 Lack of Awareness Regarding Advanced Technologies
4.4 Porter's Five Force Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5 MARKET SEGMENTATION
5.1 Disease Type
5.1.1 Hemophilia A
5.1.2 Hemophilia B
5.2.1 Replacement Therapy
5.2.2 Gene Therapy
5.2.3 Others (Immune Tolerance Induction Therapy etc.)
5.3 Product Type
5.3.1 Recombinant Coagulation Factor Concentrates
5.3.2 Plasma-derived Coagulation Factor Concentrates
5.3.3 Others (Desmopressin etc.)
5.4.1 North America
188.8.131.52 United States
184.108.40.206 United Kingdom
220.127.116.11 Rest of Europe
5.4.3 Asia Pacific
18.104.22.168 South Korea
22.214.171.124 Rest of Asia-Pacific
5.4.4 Middle East and Africa
126.96.36.199 South Africa
188.8.131.52 Rest of Middle East and Africa
5.4.5 South America
184.108.40.206 Rest of South America
6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Bayer AG
6.1.2 BioMarin Pharmaceutical, Inc.
6.1.3 CSL Behring
6.1.4 Kedrion S.p.A
6.1.5 Novo Nordisk
6.1.6 Pfizer, Inc.
6.1.7 Roche (Chugai Pharmaceutical Co.)
6.1.8 Sanofi (Genzyme Corporation)
6.1.9 Takeda Pharmaceutical (Shire Plc.)
7 MARKET OPPORTUNITIES AND FUTURE TRENDS
The dynamic nature of business environment in the current global economy is raising the need amongst business professionals to update themselves with current situations in the market. To cater such needs, Shibuya Data Count provides market research reports to various business professionals across different industry verticals, such as healthcare & pharmaceutical, IT & telecom, chemicals and advanced materials, consumer goods & food, energy & power, manufacturing & construction, industrial automation & equipment and agriculture & allied activities amongst others.
For more information, please contact: Hina Miyazu
Shibuya Data Count
Tel: + 81 3 45720790
Legal Disclaimer: MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.